• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Psychotherapy for Alcohol Use Disorder Is Associated With Reduced Risk of Incident Alcohol-Associated Liver Disease.心理疗法治疗酒精使用障碍与降低酒精相关性肝病发病风险相关。
Clin Gastroenterol Hepatol. 2023 Jun;21(6):1571-1580.e7. doi: 10.1016/j.cgh.2022.08.001. Epub 2022 Aug 11.
2
Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder.酒精使用障碍治疗后与酒精相关的肝病的发生率和进展。
JAMA Netw Open. 2022 May 2;5(5):e2213014. doi: 10.1001/jamanetworkopen.2022.13014.
3
Moderate-high intensity exercise associates with reduced incident alcohol-associated liver disease in high-risk patients.中高强度运动与高危人群中酒精相关性肝病的发病率降低有关。
Alcohol Alcohol. 2023 Sep 9;58(5):472-477. doi: 10.1093/alcalc/agad052.
4
Disentangling the contributions of alcohol use disorder and alcohol-related liver disease towards dementia: A population-based cohort study.解析酒精使用障碍和酒精性肝病对痴呆症的影响:一项基于人群的队列研究。
Addiction. 2024 Apr;119(4):706-716. doi: 10.1111/add.16395. Epub 2023 Dec 3.
5
Misclassified Alcohol-related Liver Disease is Common in Presumed Metabolic Dysfunction-associated Steatotic Liver Disease and Highly Increases Risk for Future Cirrhosis.在疑似代谢相关脂肪性肝病中,酒精性肝病常被误诊,且这种误诊极大地增加了未来发生肝硬化的风险。
Clin Gastroenterol Hepatol. 2024 May;22(5):1048-1057.e2. doi: 10.1016/j.cgh.2024.01.006. Epub 2024 Jan 17.
6
Multidisciplinary Care of Alcohol-related Liver Disease and Alcohol Use Disorder: A Narrative Review for Hepatology and Addiction Clinicians.酒精性肝病和酒精使用障碍的多学科护理:面向肝病学和成瘾临床医生的叙述性综述
Clin Ther. 2023 Dec;45(12):1177-1188. doi: 10.1016/j.clinthera.2023.09.016. Epub 2023 Oct 8.
7
Closing the Care Gap: Management of Alcohol Use Disorder in Patients with Alcohol-associated Liver Disease.缩小治疗差距:酒精性肝病患者酒精使用障碍的管理
Clin Ther. 2023 Dec;45(12):1189-1200. doi: 10.1016/j.clinthera.2023.09.017. Epub 2023 Dec 4.
8
Treatment of Alcohol Use Disorder: Behavioral and Pharmacologic Therapies.酒精使用障碍的治疗:行为和药物治疗。
Clin Liver Dis. 2024 Nov;28(4):761-778. doi: 10.1016/j.cld.2024.06.011.
9
Treating Alcohol Use Disorder in Patients with Alcohol-Associated Liver Disease: Controversies in Pharmacological Therapy.治疗酒精相关肝病患者的酒精使用障碍:药物治疗的争议。
Semin Liver Dis. 2022 May;42(2):138-150. doi: 10.1055/a-1798-2872. Epub 2022 Mar 15.
10
Covid-19 and alcohol associated liver disease.Covid-19 与酒精相关的肝病。
Dig Liver Dis. 2022 Nov;54(11):1459-1468. doi: 10.1016/j.dld.2022.07.007. Epub 2022 Aug 4.

引用本文的文献

1
Perceptions of alcohol use disorder support among liver transplant recipients: a survey of strategies and challenges.肝移植受者对酒精使用障碍支持的认知:策略与挑战调查
Front Transplant. 2025 Jun 26;4:1577086. doi: 10.3389/frtra.2025.1577086. eCollection 2025.
2
Treatment of alcohol use disorder in alcohol-associated liver disease: A meta-analysis.酒精相关性肝病中酒精使用障碍的治疗:一项荟萃分析。
Hepatol Commun. 2025 Apr 30;9(5). doi: 10.1097/HC9.0000000000000686. eCollection 2025 May 1.
3
Naltrexone for Alcohol Use Disorder in Cirrhosis: Bridging the Gap in an Understudied Population.纳曲酮用于肝硬化患者酒精使用障碍的治疗:填补对这一研究不足人群的认知空白
J Clin Exp Hepatol. 2025 Mar-Apr;15(2):102509. doi: 10.1016/j.jceh.2025.102509. Epub 2025 Jan 23.
4
The impact of integrated care on clinical outcomes in patients with alcohol-associated liver disease: Early outcomes from a multidisciplinary clinic.综合护理对酒精性肝病患者临床结局的影响:多学科诊所的早期结果
Hepatol Commun. 2025 Feb 10;9(2). doi: 10.1097/HC9.0000000000000603. eCollection 2025 Feb 1.
5
Demographic and clinical characteristics associated with utilization of alcohol use disorder treatment in a multicenter study of patients with alcohol-associated cirrhosis.在一项针对酒精性肝硬化患者的多中心研究中,与酒精使用障碍治疗利用情况相关的人口统计学和临床特征。
Alcohol Clin Exp Res (Hoboken). 2025 Jan;49(1):244-255. doi: 10.1111/acer.15500. Epub 2024 Dec 4.
6
Alcohol-associated liver disease: Natural history, management and novel targeted therapies.酒精性肝病:自然史、管理与新型靶向治疗
Clin Mol Hepatol. 2025 Feb;31(Suppl):S112-S133. doi: 10.3350/cmh.2024.0709. Epub 2024 Oct 31.
7
The urgent need for multidisciplinary approaches in managing alcohol-associated liver disease: Editorial on "The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The UK Biobank cohort study".管理酒精性肝病时对多学科方法的迫切需求:关于“精神科干预对酒精性肝病的预后影响:英国生物银行队列研究”的社论
Clin Mol Hepatol. 2025 Jan;31(1):316-318. doi: 10.3350/cmh.2024.0847. Epub 2024 Oct 7.
8
Integrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder.针对酒精性肝病和酒精使用障碍全谱系的综合协作式照护。
Hepatology. 2024 Dec 1;80(6):1408-1423. doi: 10.1097/HEP.0000000000000996. Epub 2024 Jun 27.
9
Preventive behavioral interventions for patients with steatotic liver disease.针对脂肪性肝病患者的预防性行为干预措施。
Clin Liver Dis (Hoboken). 2024 Jun 12;23(1):e0202. doi: 10.1097/CLD.0000000000000202. eCollection 2024 Jan-Jun.
10
Management of depression/anxiety in patients with chronic liver disease.慢性肝病患者抑郁/焦虑的管理
Clin Liver Dis (Hoboken). 2024 Jun 5;23(1):e0179. doi: 10.1097/CLD.0000000000000179. eCollection 2024 Jan-Jun.

心理疗法治疗酒精使用障碍与降低酒精相关性肝病发病风险相关。

Psychotherapy for Alcohol Use Disorder Is Associated With Reduced Risk of Incident Alcohol-Associated Liver Disease.

机构信息

Massachusetts General Hospital Alcohol Liver Center, Massachusetts General Hospital, Boston, Massachusetts; Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts.

Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts.

出版信息

Clin Gastroenterol Hepatol. 2023 Jun;21(6):1571-1580.e7. doi: 10.1016/j.cgh.2022.08.001. Epub 2022 Aug 11.

DOI:10.1016/j.cgh.2022.08.001
PMID:35964893
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9918606/
Abstract

BACKGROUND & AIMS: Alcohol-associated liver disease (ALD) is a devastating complication of alcohol use disorder (AUD). Once it develops, ALD is exceedingly difficult to treat; it therefore is critical to identify ways to prevent ALD. By treating the causes of increased alcohol consumption, psychotherapy may offer prophylactic benefit against the development of ALD for patients with AUD.

METHODS

In this retrospective cohort study, we used International Classification of Diseases, 9th and 10th revision, codes to identify 9635 patients with AUD in the Mass General Brigham Biobank. The mean follow-up period from AUD diagnosis was 9.2 years. We used Cox regression models to generate hazard ratios (HR) for the development of ALD given the receipt or nonreceipt of psychotherapy, adjusting for a range of other contributors including the receipt of medication-assisted treatment.

RESULTS

In our cohort, 60.4% of patients were men, 83.5% of patients were white, the median age was 57.0 years, and 3544 patients (36.8%) received psychotherapy. ALD developed in 1135 patients (11.8%). In multivariable analysis, psychotherapy was associated with a reduced rate of ALD (HR, 0.59; 95% CI, 0.50-0.71; P < .001). This association held for both individual psychotherapy (HR, 0.70; 95% CI, 0.56-0.86; P < .001) and group psychotherapy (HR, 0.76; 95% CI, 0.61-0.94; P = .01). Among patients with cirrhosis, psychotherapy was associated with a lower rate of hepatic decompensation (HR, 0.68; 95% CI, 0.48-0.95; P = .03).

CONCLUSIONS

The receipt of psychotherapy in the setting of AUD is associated with reduced incidence and progression of ALD. Given the safety and potential benefit of psychotherapy, clinicians should consider using it to prevent the development of ALD.

摘要

背景与目的

酒精相关性肝病(ALD)是酒精使用障碍(AUD)的一种严重并发症。一旦发生,ALD 极难治疗;因此,确定预防 ALD 的方法至关重要。通过治疗导致酒精摄入增加的原因,心理疗法可能会为 AUD 患者预防 ALD 的发展提供预防益处。

方法

在这项回顾性队列研究中,我们使用国际疾病分类第 9 版和第 10 版的代码在麻省总医院布里格姆生物库中确定了 9635 名 AUD 患者。从 AUD 诊断到随访的平均时间为 9.2 年。我们使用 Cox 回归模型生成了接受或未接受心理治疗的情况下发生 ALD 的风险比(HR),并根据包括接受药物辅助治疗在内的一系列其他因素进行了调整。

结果

在我们的队列中,60.4%的患者为男性,83.5%的患者为白人,中位年龄为 57.0 岁,3544 名患者(36.8%)接受了心理治疗。1135 名患者(11.8%)发生了 ALD。多变量分析显示,心理治疗与 ALD 发生率降低相关(HR,0.59;95%CI,0.50-0.71;P<.001)。这种关联适用于个体心理治疗(HR,0.70;95%CI,0.56-0.86;P<.001)和团体心理治疗(HR,0.76;95%CI,0.61-0.94;P=.01)。在肝硬化患者中,心理治疗与肝功能失代偿发生率降低相关(HR,0.68;95%CI,0.48-0.95;P=.03)。

结论

在 AUD 患者中接受心理治疗与降低 ALD 的发生率和进展相关。鉴于心理治疗的安全性和潜在益处,临床医生应考虑使用它来预防 ALD 的发生。